You are here

Home » Content

MEZENKİMAL KÖK HÜCRELERİN RATLARDA CROHN HASTALIĞI MODELİNDE DOKU HASARI, İNFLAMATUAR VE ANTİNFLAMATUAR SİTOKİNLERE ETKİSİ

EFFECTS OF MESENCHYMAL STEM CELLS ON TISSUE INJURY, INFLAMMATORY AND ANTI-INFLAMMATORY CYTOKINES IN CROHN’S DISEASE MODEL IN RATS

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Background: Mesenchymal stem cells (MSC) have immune supressive effects by decreasing inflammatory cytokines (IFN-γ, TNF-α) increasing antiinflammatory cytokines (IL-10) and inhibiting T cells and antigen presenting cells. Various cytokines are responsible for mucosal damage in Crohn‘s disease and TNF-α is one of the most important of them. The aim of this study is to determine the role of MSC in the treatment of Crohn‘s disease model. Methods: 3% Dextran sulphate sodium (DSS) is used to make Crohn‘s disease model. There are 7 groups which composed of 6 rats in each group; Group 1: SHAM group, Group 2: DSS+ placebo, Group 3: DSS+ methylprednisolone 1 mg/kg, po, Group 4: DSS + mesalazine 100 mg/kg, po., Group 5: DSS+ MKH, 106 cell/rat, intraperitoneal, Group 6: DSS + methylprednisolone 1 mg/kg, po + MSC, 106 cell/rat, intraperitoneal, Group 7: DSS + mesalazine 100 mg/kg, po + MSC, 106 cell/rat, intraperitoneal. Groups are compared with the alteration of pathological and biochemical (TNF, INF IL-10) parameters. Results: The average scores of group 1, 2 and 3 were higher than the average scores of Group 5, 6 and 7 significantly in pathological evaluation (p<0.05). IL-10 was 108.33±2.23 pg/ml in Group 1, 80.83±3.62 pg/ml in Group 2 where the levels of IL-10 were 131.66±3.83 pg/ml, 138.33±3.19 pg/ml and 115.33±5.21 pg/ml in Group 5, 6 and 7 respectively, in which MSC was used as a treatment. It is observed that the average of these three groups were significantly higher (p<0.05). Conclusion: This study suggest that MSC may take a role in the treatment of Crohn‘s disease by increasing the amount of IL-10.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Mezenkimal kök hücreler (MKH) T hücre oluĢumunu ve antijen sunan hücreleri inhibe ederek inflamatuar sitokinlerin salınımını baskılayarak (IFN-γ, TNF-α) ve antiinflamatuar sitokinlerin (IL-10) salınımını arttırarak immunsupresiv etki oluĢturmaktadırlar. Crohn hastalığında bağırsaklarda oluĢan mukozal hasarda ise birçok sitokin sorumlu olmakla birlikte TNF-α bunlar içerisinde önde gelenlerdendir. Bu çalıĢmanın amacı MKH lerin Deneysel Kolit modelinde tedavideki yerini belirlemektir. Gereç ve yöntem: Deneysel kolit oluĢturmak için %3 Dekstran sülfat sodyum (DSS) kulllanıldı. ÇalıĢma her grup da 6 sar rat olmak üzere 7 grup üzerinde yapıldı: Grup 1:SHAM grubu, Grup 2: DSS+ placebo, Grup 3: DSS+ metilprednisolon 1 mg/kg, po, Grup 4: DSS + mesalazin 100 mg/kg, po., Grup 5: DSS+ MKH,106 hücre/rat, intraperitoneal, Grup 6: DSS + metilprednisolon 1 mg/kg, po + MKH,106 hücre/rat, intraperitoneal, Grup 7: DSS + mesalazin 100 mg/kg, po + MKH, 106 hücre/rat, intraperitoneal. Gruplar patolojik ve biyokimyasal (TNF, INF IL-10) parametrelerdeki değiĢimler ölçülerek karĢılaĢtırıldı. Bulgular: Patolojik değerlendirmede Grup 1, 2 ve 3‘ün ortalama skorlarının Grup 5, 6 ve 7‘nin ortalama skorlarından belirgin yüksek olduğu gözlendi (p<0,05). IL-10 düzeyi Grup 1 için 108,33±2,23 pg/ml, Grup 2 için 80,83±3,62 pg/ml olup MKH tedavisi verilen gruplar olan Grup 5, 6 ve 7 de bu değerler sırasıyla 131,66±3,83 pg/ml, 138,33±3,19 pg/ml ve 115,33±5,21 pg/ml olarak ölçülmüĢ olup, bu son üç grup ortalamalarının anlamlı olarak yüksek olduğu gözlendi (p<0,05). IFN-γ ve TNF-α düzeyleri açısından gruplar arasında anlamlı bir fark bulunmadı. Sonuç: Bu çalıĢmanın sonucuna göre MKH‘in IL-10 düzeyini yükselterek Crohn hastalığı tedavisinde yeri olabileceği düĢünülebilir
FULL TEXT (PDF): 
PDF icon arastirmax-mezenkimal-kok-hucrelerin-ratlarda-crohn-hastaligi-modelinde-doku-hasari-inflamatuar-antinflamatuar-sitokinlere-etkisi.pdf
  • 4
59-63
  • Turkish

REFERENCES

References: 

1. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stem cells: Nature, biology, and potential applications. Stem Cells 2001; 19: 180-192.
2. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98: 2396-2402
3. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-650.
4. Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA 2000; 97: 3213-3218.
5. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, van Deventer S. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342:173-174.
6. Devine SM, Cobbs C Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusions into nonhuman primates. Blood 2003; 101: 2009-3001.
7. Fedorak RW, Empley LR, Walker K. Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats. Gastroenterology 1992; 102: 1229-1235.
8. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by ınhibiting ınflammatory and autoimmune responses. Gastroenterology 2009; 136: 978-989.
9. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58: 929-939.
10. Helm GA, Gazit Z. Future uses of mesenchymal stem cells in spine surgery. Neurosurg Focus 2005; 19:E13.
11. Irvine EJ, Farrokhyar F, Swarbrick ET. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 2-15.
12. Kemp KC, Hows J, Donaldson C. Bonemarrow-derived mesenchymal stem cells. Leuk Lymphoma 2005; 46: 1531-1544.
13. Krabbe C, Zimmer J, Meyer M. Neural transdifferentiation of mesenchymal stem cells-a critical review. APMIS 2005; 113:831-844.
14. Le Blanc K, Rıngden O. Immunomodulation by mesenchymal stem cells and clinical experience. Journal of Internal Medicine 2007; 262: 509-525.
15. MacDermott RP. Progress in understanding the mechanisms of action of 5- aminosalicylic acid. Am J Gastroenterol 2000; 95: 3343-3345.
16. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-989.
17. Misiewicz JJ, Lond MB. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; 2: 185.
18. Moore KL. The developing human: Clinically oriented embriology. In: Moore KL (ed). The Developing Human.WB Saunders, Philadelphia, London, 4th ed. ,1988.
19. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362.
20. Munkholm P. Crohn's disease—occurrence, course and prognosis: An epidemiologic cohort-study. Dan Med Bull 1997; 44: 287-302.
21. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
22. Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. Mech Ageing Dev 2001; 122: 713-734.
23. Sands BE. Crohn‘s Disease. In: Feldman M. (ed). Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 8 th ed. Saunders, 2006: pp 2459-2498.
24. Sands BE. Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 323-351.
25. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: A randomized study. N Engl J Med 1987; 317: 1625-1629.
26. Scotiniotis I, Rubesin SE, Ginsberg GG. Imaging modalities in inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28:391-421.
27. Su C, Lichtenstein GR. Ulcerative Colitis. In: Feldman M (ed). Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 8th ed. Saunders, 2006: pp 2499-2548.
28. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. BMJ 1955; 2: 1041-1048.
29. Uccelli A, Zappia E, Benvenuto F, Frassoni F, Mancardi G. Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opin Biol Ther 2006; 6:17-22.

Thank you for copying data from http://www.arastirmax.com